Clinical trials: Non-relapsing Secondary Progressive Multiple Sclerosis, open to volunteers

Multiple Sclerosis, Multiple Sclerosis, Primary Progressive

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

• Recruiting
• Age: 18 to 65 years
• Phase 1

A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis

Conditions

Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive

Trial name

NCT06138132

Testing

KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen

Where

United States

Volunteers

12 people

Sponsor

Stanford University